HDAC9 and neoplasm: With promising preclinical results, molecules such as PI3Kγ and histone deacetylases (HDAC) inhibitors have achieved the reprogramming of TAMs toward an anti‐tumor phenotype state, resulting in a decrease in tumor growth together with increased tumor sensitization to immune checkpoint inhibitors,9 data that demonstrate the potential clinical efficacy of this therapeutic strategy.5, 6